Related Experiment Video
Updated: Jul 16, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
[Metastatic renal cell carcinoma and its treatments]
1Unité d'immunothérapie, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif, France. escudier@igr.fr
Abstract:
The treatment of metastatic renal cell carcinoma is deeply evolving. After the cytokines, interleukin 2 and interferon era, which raised great expectations followed by deep disillusions (related to an efficacy limited to a small group of patients and an important toxicity for a majority of them), the time of targeted therapies has come. These new therapies mainly work on the VHL-HIF way, which controls several key molecules involved in the tumour angiogenesis phenomena, especially the VEGF. Several drugs currently being developed allow to stop either the circulating angiogenic factors (mainly the VEGF), or the tyrosine kinase receptors, especially the VEGF and the PDGF receptors. The reported activity and potential of these drugs are: tumour reduction, improvement of progression-free survival, effects on the overall survival. Currently, 4 among these drugs are in phase III (sorafenib, sunitinib, bevacizumab and temsirolimus), sorafenib and sunitinib have been allowed by the FDA, in the USA, and by the EMEA, in Europe, in the treatment of advanced renal cell carcinoma.
Insights
Targeted therapies represent a new era in treating metastatic renal cell carcinoma, offering improved outcomes. These novel treatments focus on tumor angiogenesis pathways, showing significant potential for advanced kidney cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Context:
- Metastatic renal cell carcinoma (mRCC) treatment has evolved significantly.
- Previous cytokine therapies (interleukin-2, interferon) showed limited efficacy and high toxicity.
- Targeted therapies offer a new paradigm for mRCC management.
Purpose:
- To review the emergence and potential of targeted therapies in metastatic renal cell carcinoma.
- To highlight the mechanisms of action, focusing on the VHL-HIF pathway and angiogenesis.
- To summarize the clinical development and regulatory status of key targeted agents.
Summary:
- Targeted therapies primarily inhibit tumor angiogenesis by targeting vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors.
- Drugs like sorafenib, sunitinib, bevacizumab, and temsirolimus are in late-stage clinical trials.
- These agents demonstrate tumor reduction, improved progression-free survival, and potential overall survival benefits.
Impact:
- Approved targeted therapies (sorafenib, sunitinib) offer new treatment options for advanced renal cell carcinoma.
- This evolving field promises better patient outcomes and reduced toxicity compared to older treatments.
- Further research into targeted therapies is crucial for optimizing mRCC management.
More Related Videos
Related Concept Videos
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
02:56Treatment Resistent Cancers